suibowen2010

版主

應(yīng)助: 0 (幼兒園)
金幣: 2148.1
帖子: 237
在線: 42小時(shí)
蟲(chóng)號(hào): 944649

[交流] 求高人幫翻譯一段說(shuō)明書急~

1 General
Responding patients may not experience an improvement in performance status on therapy and
may experience worsening. The relationship between changes in performance status, response to
therapy, and treatment-related side effects has not been established.

2 Cutaneous
Localized erythema of the extremities with edema followed by desquamation has been observed.
In case of severe skin toxicity, an adjustment in dosage is recommended [see Dose Adjustments
During Treatment (2.7)]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for
metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day
corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued
TAXOTERE due to skin toxicity.

3 Fluid Retention
Severe fluid retention has been reported following TAXOTERE therapy [see Boxed Warning,
Premedication Regimen (2.6)]. Patients should be premedicated with oral corticosteroids prior
to each TAXOTERE administration to reduce the  incidence and severity of fluid retention [see
Premedication Regimen (2.6)]. Patients with pre-existing effusions should be closely monitored
from the first dose for the possible exacerbation of the effusions.

When fluid retention occurs, peripheral edema usually starts in the lower extremities and may
become generalized with a median weight gain of 2 kg.

Among 92 breast cancer patients premedicated  with 3-day corticosteroids, moderate fluid
retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to
onset of moderate or severe fluid retention was 819 mg/m2. 9.8% (9/92) of patients discontinued
treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the
remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment
discontinuation due to fluid retention was 1021 mg/m2. Fluid retention was completely, but
sometimes slowly, reversible with a median of 16 weeks from the last infusion of TAXOTERE
to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with
standard measures, e.g., salt restriction, oral diuretic(s).

4 Neurologic
Severe neurosensory symptoms (paresthesia, dysesthesia, pain) were observed in 5.5% (53/965)
of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When
these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be
discontinued  [see Dose Adjustments During Treatment (2.7)]. Patients who experienced
neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of
the event was available had spontaneous reversal of symptoms with a median of 9 weeks from
onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal
extremity weakness occurred in 4.4% (42/965).

5 Asthenia
Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has
led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few
days up to several weeks and may be associated with deterioration of  performance status in
patients with progressive disease.

6. ADVERSE  REACTIONS
Adverse reactions are described for TAXOTERE according to indication.

6.1  Clinical Trial Experience

• Breast Cancer

Monotherapy with TAXOTERE for locally advanced or metastatic breast cancer after
failure of prior chemotherapy
TAXOTERE 100 mg/m2: Adverse drug reactions occurring in at least 5% of patients are
compared for three populations who received TAXOTERE administered at 100 mg/m2
as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function
tests; and an additional 61 patients with various tumor types who had abnormal liver function
tests at baseline. These reactions were described using COSTART terms and were considered
possibly or probably related to TAXOTERE. At least 95% of these patients did not receive
hematopoietic support. The safety profile is generally similar in patients receiving TAXOTERE
for the treatment of breast cancer and in patients with other tumor types (See Table 4).

回復(fù)此樓

» 猜你喜歡

307分求調(diào)劑已經(jīng)有12人回復(fù)
0817化工學(xué)碩調(diào)劑已經(jīng)有9人回復(fù)
319求調(diào)劑已經(jīng)有6人回復(fù)
320分，材料與化工專業(yè)，求調(diào)劑已經(jīng)有16人回復(fù)
316求調(diào)劑已經(jīng)有10人回復(fù)
291求調(diào)劑已經(jīng)有19人回復(fù)
353求調(diào)劑已經(jīng)有4人回復(fù)
08生物與醫(yī)藥專碩初試346找調(diào)劑已經(jīng)有4人回復(fù)
337求調(diào)劑已經(jīng)有9人回復(fù)
生物與醫(yī)藥考研調(diào)劑已經(jīng)有5人回復(fù)

» 搶金幣啦！回帖就可以得到:

查看全部散金貼

1樓 2011-04-01 16:44:57

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

ljason

版主

翻譯EPI: 30
應(yīng)助: 404 (碩士)
金幣: 381.5
帖子: 78709
在線: 2205小時(shí)
蟲(chóng)號(hào): 904684

suibowen2010(金幣+1, 翻譯EPI+1): 額~確實(shí)是都翻譯不過(guò)我已經(jīng)翻譯完了呵呵 2011-04-06 20:58:54
Mally89(翻譯EPI-1): 無(wú)效應(yīng)助！~收回EPI，多謝理解合作！~歡迎常來(lái)翻譯求助版！~好運(yùn)！~ 2011-04-07 09:41:23

lz要翻譯哪一部分，不會(huì)都翻譯吧

贊一下(1人)

回復(fù)此樓

3樓2011-04-06 14:46:32

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

hulinzhou

版主

應(yīng)助: 0 (幼兒園)
金幣: 933.2
帖子: 418
在線: 18.7小時(shí)
蟲(chóng)號(hào): 482780

suibowen2010(金幣+1): 確實(shí)是挺長(zhǎng)的啊不過(guò)我已經(jīng)翻譯完了！ 2011-04-06 20:59:25

這么長(zhǎng)

回復(fù)此樓

4樓2011-04-06 15:01:20

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

簡(jiǎn)單回復(fù)

Mally892樓

2011-04-01 16:57 回復(fù)

suibowen2010(金幣+1, 翻譯EPI+1): 嘿嘿沒(méi)有辦法啊任務(wù)...看的不是很到位很多話不知道怎么說(shuō) 所以才來(lái)這求助高人啊~ 2011-04-01 19:48:04
ringzhu(翻譯EPI-1): 無(wú)效應(yīng)助 2011-04-06 12:41:16

哇！

最具人氣熱帖推薦 [查看全部]	作者	回/看	最后發(fā)表

[考研] 319求調(diào)劑 +6	太容易1018 2026-04-01	6/300	2026-04-01 18:14 by 無(wú)際的草原
[考研] 337求調(diào)劑 +9	《樹(shù)》 2026-03-29	9/450	2026-04-01 18:05 by 記事本2026
[考研] 362求調(diào)劑 +13	西南交材料專碩3 2026-03-31	13/650	2026-04-01 17:38 by JYD2011
[考研] 0703求調(diào)劑 +4	zizimo 2026-03-31	4/200	2026-04-01 16:04 by yanflower7133
[考研] 309求調(diào)劑 +8	gajsj 2026-03-25	10/500	2026-04-01 14:48 by ZXlzxl0425
[考研] 08工科，295，接受跨專業(yè)調(diào)劑 +6	lmnlzy 2026-03-31	6/300	2026-04-01 11:02 by 逆水乘風(fēng)
[考研] 求調(diào)劑0703 +4	周嘉堯 2026-03-31	7/350	2026-04-01 10:36 by 周嘉堯
[考研] 318一志愿吉林大學(xué)生物與醫(yī)藥求調(diào)劑 +6	篤行致遠(yuǎn). 2026-03-28	6/300	2026-04-01 09:28 by oooqiao
[考研] 考研調(diào)劑 +9	小蠟新筆 2026-03-29	10/500	2026-03-31 19:52 by Dyhoer
[考研] 合肥區(qū)域性重點(diǎn)一本招收調(diào)劑 +4	6266jl 2026-03-30	8/400	2026-03-31 18:43 by 6266jl
[考研] 08開(kāi)頭看過(guò)來(lái)�。�！ +3	wwwwffffff 2026-03-31	5/250	2026-03-31 17:45 by 星光/
[考研] 340求調(diào)劑 +4	希望如此i 2026-03-31	4/200	2026-03-31 16:40 by 690616278
[考研] 求化學(xué)調(diào)劑 +12	wulanna 2026-03-28	12/600	2026-03-31 16:38 by 690616278
[考研] 313求調(diào)劑 +6	賣個(gè)關(guān)子吧 2026-03-31	6/300	2026-03-31 10:58 by Jaylen.
[考研] 11408總分309，一志愿東南大學(xué)求調(diào)劑，不挑專業(yè) +5	天賦帶到THU 2026-03-29	6/300	2026-03-30 20:49 by dick_runner
[考研] 298求調(diào)劑 +3	種圣賜 2026-03-29	3/150	2026-03-29 12:06 by longlotian
[碩博家園] 招收生物學(xué)/細(xì)胞生物學(xué)調(diào)劑 +4	IceGuo 2026-03-26	5/250	2026-03-29 01:25 by griffith2014
[考研] 340求調(diào)劑 +5	jhx777 2026-03-27	5/250	2026-03-28 04:18 by fmesaito
[考研] 考研調(diào)劑 +9	小蠟新筆 2026-03-26	9/450	2026-03-27 11:10 by 不吃魚的貓
[考研] 一志愿吉大071010，316分求調(diào)劑 +3	xgbiknn 2026-03-27	3/150	2026-03-27 10:36 by guoweigw